{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T10:19:17Z","timestamp":1769854757010,"version":"3.49.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s11864-020-00758-4","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T14:03:07Z","timestamp":1595944987000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Consolidation Therapy in Primary Central Nervous System Lymphoma"],"prefix":"10.1007","volume":"21","author":[{"given":"Peter","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Omuro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,28]]},"reference":[{"issue":"1","key":"758_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0360-3016(81)90060-2","volume":"7","author":"MP Berry","year":"1981","unstructured":"Berry MP, Simpson W. Radiation therapy in the management of primary malignant lymphoma of the brain. Int J Radiat Oncol Biol Phys. 1981;7(1):55\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"758_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0360-3016(92)90538-S","volume":"23","author":"DF Nelson","year":"1992","unstructured":"Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman HD, et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the radiation therapy oncology group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 1992;23(1):9\u201317.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"758_CR3","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3171\/jns.1989.70.2.0190","volume":"70","author":"AA Gabbai","year":"1989","unstructured":"Gabbai AA, Hochberg FH, Linggood RM, Bashir R, Holteman K. High-dose methotrexate for non-AIDS primary central nervous system lymphoma. J Neurosurg. 1989;70:190\u20134.","journal-title":"J Neurosurg"},{"issue":"4","key":"758_CR4","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1200\/JCO.1992.10.4.635","volume":"10","author":"LM Deangelis","year":"1992","unstructured":"Deangelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J Clin Oncol. 1992;10(4):635\u201343.","journal-title":"J Clin Oncol"},{"issue":"6","key":"758_CR5","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1200\/JCO.2003.03.036","volume":"21","author":"T Batchelor","year":"2003","unstructured":"Batchelor T, Carson K, O\u2019Neill A, Grossman SA, Alavi J, New P, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96\u201307. J Clin Oncol. 2003;21(6):1044\u20139.","journal-title":"J Clin Oncol"},{"key":"758_CR6","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1200\/EDBK_242547","volume":"39","author":"AJM Ferreri","year":"2019","unstructured":"Ferreri AJM, Holdhoff M, Nayak L, Rubenstein JL. Evolving treatments for primary central nervous system lymphoma. Am Soc Clin Oncol Educ Book. 2019;39:454\u201366.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"758_CR7","doi-asserted-by":"crossref","unstructured":"Schaff LR, Grommes C. Updates on primary central nervous system lymphoma. Curr Oncol Rep. 2018 Feb 28;20(2):11.","DOI":"10.1007\/s11912-018-0666-1"},{"issue":"24","key":"758_CR8","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.1200\/JCO.2002.11.013","volume":"20","author":"LM Deangelis","year":"2002","unstructured":"Deangelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: radiation therapy oncology group study 93-10. J Clin Oncol. 2002;20(24):4643\u20138.","journal-title":"J Clin Oncol"},{"issue":"3","key":"758_CR9","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1200\/JCO.1998.16.3.859","volume":"16","author":"LE Abrey","year":"1998","unstructured":"Abrey LE, Deangelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol. 1998;16(3):859\u201363.","journal-title":"J Clin Oncol"},{"issue":"10","key":"758_CR10","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1001\/archneur.62.10.1595","volume":"62","author":"AMP Omuro","year":"2005","unstructured":"Omuro AMP, Ben-Porat LS, Panageas KS, Kim AK, Correa DD, Yahalom J, et al. Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol. 2005;62(10):1595\u2013600.","journal-title":"Arch Neurol"},{"issue":"1","key":"758_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/neuonc\/nor186","volume":"14","author":"DD Correa","year":"2011","unstructured":"Correa DD, Shi W, Abrey LE, Deangelis LM, Omuro AMP, Deutsch MB, et al. Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro-Oncology. 2011;14(1):101\u20138.","journal-title":"Neuro-Oncology"},{"issue":"1","key":"758_CR12","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1212\/WNL.0b013e318297eeba","volume":"81","author":"ND Doolittle","year":"2013","unstructured":"Doolittle ND, Korfel A, Lubow MA, Schorb E, Schlegel U, Rogowski S, et al. Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma. Neurology. 2013;81(1):84\u201392.","journal-title":"Neurology"},{"issue":"9","key":"758_CR13","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1007\/s00432-017-2423-5","volume":"143","author":"U Herrlinger","year":"2017","unstructured":"Herrlinger U, Sch\u00e4fer N, Fimmers R, Griesinger F, Rauch M, Kirchen H, et al. Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial. J Cancer Res Clin Oncol. 2017;143(9):1815\u201321.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"7","key":"758_CR14","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1093\/annonc\/mdv076","volume":"26","author":"B Kasenda","year":"2015","unstructured":"Kasenda B, Ferreri AJM, Maturano E, et al. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL) \u2013 a systematic review and individual patient data meta-analysis. Ann Oncol. 2015;26(7):1305\u201313.","journal-title":"Ann Oncol"},{"issue":"11","key":"758_CR15","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/S1470-2045(10)70229-1","volume":"11","author":"E Thiel","year":"2015","unstructured":"\u2022 Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2015;11(11):1036\u201347 Phase 3 trial suggesting further role for radiation as a consolidation therapy.","journal-title":"Lancet Oncol"},{"issue":"12","key":"758_CR16","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1212\/WNL.0000000000001395","volume":"84","author":"A Korfel","year":"2015","unstructured":"Korfel A, Thiel E, Martus P, M\u00f6hle R, Griesinger F, Rauch M, et al. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology. 2015;84(12):1242\u20138.","journal-title":"Neurology"},{"issue":"11","key":"758_CR17","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S2352-3026(17)30174-6","volume":"4","author":"F AJM","year":"2017","unstructured":"\u2022 AJM F, Cwynarski K, Pulczynski E, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017;4(11):e510\u201323 Large phase 2 comparative study between WBRT and HDC-ASCT displaying similar outcomes at the risk of delayed neurotoxicity from WBRT.","journal-title":"Lancet Haematol"},{"issue":"10","key":"758_CR18","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1200\/JCO.18.00306","volume":"37","author":"C Houillier","year":"2019","unstructured":"\u2022 Houillier C, Taillandier L, Dureau S, et al. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study. J Clin Oncol. 2019;37(10):823\u201333 Large phase 2 comparative study between WBRT and HDC-ASCT highlighting TRM from HDC-ASCT, but significantly decreased relapse rates.","journal-title":"J Clin Oncol"},{"issue":"1","key":"758_CR19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.2002.20.1.231","volume":"20","author":"EM Bessell","year":"2002","unstructured":"Bessell EM, L\u00f3pez-Guillermo A, Vill\u00e1 S, Verger E, Nomdedeu B, Petit J, et al. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD\/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol. 2002;20(1):231\u20136.","journal-title":"J Clin Oncol"},{"issue":"2","key":"758_CR20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s11060-004-6596-9","volume":"74","author":"B Fisher","year":"2005","unstructured":"Fisher B, Seiferheld W, Schultz C, Deangelis L, Nelson D, Schold SC, et al. Secondary analysis of radiation therapy oncology group study (RTOG) 9310: an intergroup phase II combined modality treatment of primary central nervous system lymphoma. J Neuro-Oncol. 2005;74(2):201\u20135.","journal-title":"J Neuro-Oncol"},{"issue":"14","key":"758_CR21","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1200\/JCO.2015.64.8634","volume":"34","author":"J Glass","year":"2016","unstructured":"Glass J, Won M, Schultz CJ, Brat D, Bartlett NL, Suh JH, et al. Phase I and II study of induction chemotherapy with methotrexate, rituximab, and Temozolomide, followed by whole-brain radiotherapy and Postirradiation Temozolomide for primary CNS lymphoma: NRG oncology RTOG 0227. J Clin Oncol. 2016;34(14):1620\u20135.","journal-title":"J Clin Oncol"},{"issue":"30","key":"758_CR22","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.1200\/JCO.2007.12.5062","volume":"25","author":"GD Shah","year":"2007","unstructured":"Shah GD, Yahalom J, Correa DD, Lai RK, Raizer JJ, Schiff D, et al. Combined Immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2007;25(30):4730\u20135.","journal-title":"J Clin Oncol"},{"issue":"31","key":"758_CR23","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1200\/JCO.2013.50.4910","volume":"31","author":"PG Morris","year":"2013","unstructured":"Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, et al. Rituximab, methotrexate, Procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and Cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013;31(31):3971\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"758_CR24","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s11060-019-03257-1","volume":"144","author":"DD Correa","year":"2019","unstructured":"Correa DD, Braun E, Kryza-Lacombe M, Ho KW, Reiner AS, Panageas KS, et al. Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation. J Neuro-Oncol. 2019;144(3):553\u201362.","journal-title":"J Neuro-Oncol"},{"issue":"6","key":"758_CR25","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1097\/WCO.0000000000000619","volume":"31","author":"U Schlegel","year":"2018","unstructured":"Schlegel U, Korfel A. Is whole-brain radiotherapy still a standard treatment for primary central nervous system lymphomas? Curr Opin Neurol. 2018;31(6):733\u20139.","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"758_CR26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11060-018-2856-y","volume":"139","author":"N Adhikari","year":"2018","unstructured":"Adhikari N, Biswas A, Gogia A, Sahoo RK, Garg A, Nehra A, et al. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome. J Neuro-Oncol. 2018;139(1):153\u201366.","journal-title":"J Neuro-Oncol"},{"issue":"5","key":"758_CR27","first-page":"1021","volume":"18","author":"S Khalfallah","year":"1996","unstructured":"Khalfallah S, Stamatoullas A, Fruchart C, Proust F, Delangre T, Tilly H. Durable remission of a relapsing primary central nervous system lymphoma after autologous bone marrow transplantation. Bone Marrow Transplant. 1996;18(5):1021\u20133.","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"758_CR28","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1200\/JCO.1996.14.11.3036","volume":"14","author":"KV Besien","year":"1996","unstructured":"Besien KV, Przepiorka D, Mehra R, Giralt S, Khouri I, Gajewski J, et al. Impact of preexisting CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies. J Clin Oncol. 1996;14(11):3036\u201342.","journal-title":"J Clin Oncol"},{"issue":"3\u20134","key":"758_CR29","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3109\/10428199609054837","volume":"23","author":"C Soussain","year":"1996","unstructured":"Soussain C, Merle-B\u00e9ral H, Reux I, Sutton L, Fardeau C, Gerber S, et al. A single-center study of 11 patients with intraocular lymphoma treated with conventional chemotherapy followed by high-dose chemotherapy and autologous bone marrow transplantation in 5 cases. Leuk Lymphoma. 1996;23(3\u20134):339\u201345.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"758_CR30","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1200\/JCO.2001.19.3.742","volume":"19","author":"C Soussain","year":"2001","unstructured":"Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol. 2001;19(3):742\u20139.","journal-title":"J Clin Oncol"},{"issue":"15","key":"758_CR31","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1200\/JCO.2007.13.5533","volume":"26","author":"C Soussain","year":"2008","unstructured":"Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Mo\u00eblle Osseuse-Th\u00e9rapie Cellulaire. J Clin Oncol. 2008;26(15):2512\u20138.","journal-title":"J Clin Oncol"},{"issue":"22","key":"758_CR32","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1200\/JCO.2003.05.024","volume":"21","author":"LE Abrey","year":"2003","unstructured":"Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, et al. Intensive methotrexate and Cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol. 2003;21(22):4151\u20136.","journal-title":"J Clin Oncol"},{"issue":"24","key":"758_CR33","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1200\/JCO.2006.06.2117","volume":"24","author":"G Illerhaus","year":"2006","unstructured":"Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G, et al. High-dose chemotherapy with autologous stem-cell transplantation and Hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol. 2006;24(24):3865\u201370.","journal-title":"J Clin Oncol"},{"issue":"6","key":"758_CR34","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/sj.bmt.1705452","volume":"38","author":"P Colombat","year":"2006","unstructured":"Colombat P, Lemevel A, Bertrand P, et al. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant. 2006;38(6):417\u201320.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"758_CR35","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1093\/annonc\/mdl458","volume":"18","author":"M Montemurro","year":"2007","unstructured":"Montemurro M, Kiefer T, Sch\u00fcler F, al-Ali HK, Wolf HH, Herbst R, et al. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan\/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe H\u00e4mato-Onkologie OSHO-53 phase II study. Ann Oncol. 2007;18(4):665\u201371.","journal-title":"Ann Oncol"},{"issue":"9","key":"758_CR36","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","volume":"125","author":"A Omuro","year":"2015","unstructured":"\u2022 Omuro A, Correa DD, Deangelis LM, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015;125(9):1403\u201310 Phase 2 trial highlighting the potential for cure in treating PCNSL patients with HDC-ASCT.","journal-title":"Blood"},{"issue":"1","key":"758_CR37","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3324\/haematol.11771","volume":"93","author":"G Illerhaus","year":"2008","unstructured":"Illerhaus G, Muller F, Feuerhake F, Schafer A-O, Ostertag C, Finke J. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica. 2008;93(1):147\u20138.","journal-title":"Haematologica."},{"issue":"8","key":"758_CR38","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.1016\/S2352-3026(16)30050-3","volume":"3","author":"G Illerhaus","year":"2016","unstructured":"Illerhaus G, Kasenda B, Ihorst G, Egerer G, Lamprecht M, Keller U, et al. High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Lancet Haematol. 2016;3(8):e388\u201397.","journal-title":"Lancet Haematol"},{"issue":"3","key":"758_CR39","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.1016\/j.clml.2018.11.018","volume":"19","author":"I Alnahhas","year":"2019","unstructured":"Alnahhas I, Jawish M, Alsawas M, Zukas A, Prokop L, Murad MH, et al. Autologous stem-cell transplantation for primary central nervous system lymphoma: systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2019;19(3):e129\u201341.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"758_CR40","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/cncr.29023","volume":"121","author":"Y-B Chen","year":"2015","unstructured":"Chen Y-B, Batchelor T, Li S, Hochberg E, Brezina M, Jones S, et al. Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma. Cancer. 2015;121(2):226\u201333.","journal-title":"Cancer."},{"issue":"5","key":"758_CR41","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1212\/01.wnl.0000300671.37279.0e","volume":"70","author":"ER Gerstner","year":"2008","unstructured":"Gerstner ER, Carson KA, Grossman SA, Batchelor TT. Long-term outcome in Pcnsl patients treated with high-dose methotrexate and deferred radiation. Neurology. 2008;70(5):401\u20132.","journal-title":"Neurology"},{"issue":"3","key":"758_CR42","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1212\/WNL.0000000000000593","volume":"83","author":"M Holdhoff","year":"2014","unstructured":"Holdhoff M, Ambady P, Abdelaziz A, Sarai G, Bonekamp D, Blakeley J, et al. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology. 2014;83(3):235\u20139.","journal-title":"Neurology"},{"issue":"14","key":"758_CR43","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1200\/JCO.2003.11.036","volume":"21","author":"K Hoang-Xuan","year":"2003","unstructured":"Hoang-Xuan K, Taillandier L, Chinot O, Soubeyran P, Bogdhan U, Hildebrand J, et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol. 2003;21(14):2726\u201331.","journal-title":"J Clin Oncol"},{"issue":"4","key":"758_CR44","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1158\/1078-0432.CCR-11-0625","volume":"18","author":"MJ Wieduwilt","year":"2012","unstructured":"Wieduwilt MJ, Valles F, Issa S, Behler CM, Hwang J, McDermott M, et al. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res. 2012;18(4):1146\u201355.","journal-title":"Clin Cancer Res"},{"issue":"25","key":"758_CR45","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","volume":"31","author":"JL Rubenstein","year":"2013","unstructured":"Rubenstein JL, Hsi ED, Johnson JL, Jung S-H, Nakashima MO, Grant B, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013;31(25):3061\u20138.","journal-title":"J Clin Oncol"},{"issue":"7","key":"758_CR46","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/jnci\/92.7.575","volume":"92","author":"M Reni","year":"2000","unstructured":"Reni M. Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma. J Natl Cancer Inst. 2000;92(7):575\u20136.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"758_CR47","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.1016\/S2352-3026(15)00074-5","volume":"2","author":"A Omuro","year":"2015","unstructured":"Omuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V, et al. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Lancet Haematol. 2015;2(6):e251\u20139.","journal-title":"Lancet Haematol."},{"issue":"2","key":"758_CR48","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s11060-017-2435-7","volume":"133","author":"C Houillier","year":"2017","unstructured":"Houillier C, Ghesqui\u00e8res H, Chabrot C, Soussain C, Ahle G, Choquet S, et al. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study. J Neuro-Oncol. 2017;133(2):315\u201320.","journal-title":"J Neuro-Oncol"},{"issue":"4","key":"758_CR49","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/leu.2016.334","volume":"31","author":"K Fritsch","year":"2016","unstructured":"Fritsch K, Kasenda B, Schorb E, Hau P, Bloehdorn J, M\u00f6hle R, et al. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia. 2016;31(4):846\u201352.","journal-title":"Leukemia."},{"issue":"7","key":"758_CR50","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1093\/annonc\/mdv076","volume":"26","author":"B Kasenda","year":"2015","unstructured":"Kasenda B. Ferreri Andr\u00e9s J.m., Maturano E, et al. first-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL) \u2013 a systematic review and individual patient data meta-analysis. Ann Oncol. 2015;26(7):1305\u201313.","journal-title":"Ann Oncol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-020-00758-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-020-00758-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-020-00758-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T20:43:20Z","timestamp":1650228200000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-020-00758-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,28]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["758"],"URL":"https:\/\/doi.org\/10.1007\/s11864-020-00758-4","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,28]]},"assertion":[{"value":"28 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Peter Kim does not have any conflict of interest to disclose. Antonio Omuro has received compensation from BTG, Merck, and Inovio for service as a consultant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"74"}}